摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Pikrotoxinin | 17617-45-7

中文名称
——
中文别名
——
英文名称
Pikrotoxinin
英文别名
Picrotoxinine;1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione
Pikrotoxinin化学式
CAS
17617-45-7
化学式
C15H16O6
mdl
——
分子量
292.288
InChiKey
PIMZUZSSNYHVCU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    203-205°C
  • 比旋光度:
    D17 +4.4° (c = 4.28 in abs alc), +3.49° (c = 7.57 in acetone)
  • 沸点:
    354.22°C (rough estimate)
  • 密度:
    1.2207 (rough estimate)
  • LogP:
    -0.130 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    21
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    85.4
  • 氢给体数:
    1
  • 氢受体数:
    6

安全信息

  • 危险等级:
    6.1(a)
  • 危险品标志:
    T+
  • 安全说明:
    S13,S20,S28,S36/37,S45
  • 危险类别码:
    R25,R28
  • WGK Germany:
    3
  • 危险品运输编号:
    UN 3172
  • RTECS号:
    PC5150000
  • 包装等级:
    I
  • 危险类别:
    6.1(a)

SDS

SDS:66831635e712f155c6940a4098635b33
查看

制备方法与用途

生物活性方面,吡咯托品是一种有效的惊厥药物,它能够阻断通道。作为一种非竞争性GABAA受体拮抗剂,吡咯托品会负向调节GABAGABAA受体的激活作用。

文献信息

  • Oral pharmaceutical formulation for weight loss, diabetes and related disorders
    申请人:Lee Tien-Li
    公开号:US10835505B2
    公开(公告)日:2020-11-17
    There is disclosed an oral pharmaceutical formulation of bitter compounds that are agonists of taste receptor type 2 (TAS2R) receptors for the function of appetite suppression for the treatment of obesity. More specifically, the present disclosure provides an anti-obesity oral formulation comprising a bitter agent selected from the group consisting of denatonium salts including benzoate (DB), chloride (DC), acetate (DA), citrate (DCl), saccharide (DS), tartarate (DT), maleate (DM), 3-caffeoylquinic-1,5-lactone (3-CQL), chlorogenic acids (CGA), combinations thereof, and pharmaceutical excipients to facilitate a sustained release during transit through the gastrointestinal (GI) tract. Preferably, the oral pharmaceutical formulation further comprises either or both a sweet antagonist selected from the group consisting of lactisole, gymnemic acid, ziziphin, hodulcine, and combinations thereof, and a sour organic acid.
    本发明公开了一种苦味化合物的口服药物制剂,这些苦味化合物是味觉受体2型(TAS2R)受体的激动剂,具有抑制食欲的功能,可用于治疗肥胖症。更具体地说,本公开提供了一种抗肥胖口服制剂,其包含的苦味剂选自包括苯甲酸盐 (DB)、化物 (DC)、醋酸盐 (DA)、柠檬酸盐 (DCl)、糖苷 (DS)、酒石酸盐 (DT)、马来酸盐 (DM)、3-咖啡酰奎宁-1,5-内酯 (3-CQL)、绿原酸 (CGA)、它们的组合,以及药用辅料,以促进在胃肠道转运过程中的持续释放。优选地,口服药物制剂进一步包含选自乳异唑、钩藤碱紫草素、霍豆碱及其组合的甜味拮抗剂和酸味有机酸中的一种或两种。
  • PLANT-BASED CHEMICALS FOR VARROA MITE CONTROL
    申请人:Board Of Trustees Of Michigan State University
    公开号:EP4003330A1
    公开(公告)日:2022-06-01
  • [EN] PLANT-BASED CHEMICALS FOR VARROA MITE CONTROL<br/>[FR] PRODUITS CHIMIQUES À BASE DE PLANTES POUR LA LUTTE CONTRE LES ACARIENS VARROA
    申请人:UNIV MICHIGAN STATE
    公开号:WO2021021939A1
    公开(公告)日:2021-02-04
    Described herein are compositions and methods for killing or inhibiting honey bee parasites such as Varroa mites.
查看更多

同类化合物

马桑宁内酯 薁并[6,5-b]呋喃-2,4-二酮,十氢-5-(3-羟基丙氧基)-3a,4a-二甲基- 苦毒浆果[木防已属] 苦亭 艾瑞布林中间体 艾瑞布林 甲磺酸艾日布林 木防己苦毒宁 呋喃并[4,3,2-ij][2]苯并吡喃-2,7-二酮,2a,3,4,6,8a,8b-六氢-6-甲基-5-[(1S)-1,3,3-三甲基环己基]-,(2aR,6R,8aS,8bR)- 全内酯 二氢苦毒宁 6-甲基-4-氧代-4H-呋喃并[3,2-c]吡喃-3-甲酰氯 6-(4-羟基苯基)-2,3,3-三甲基-2H-呋喃并[5,4-b]吡喃-4-酮 4H-呋喃并[2,3-c]吡喃基莫匹罗星钠 3-甲基2H-呋喃并[2,3-c]吡喃-2-酮 3,5-二甲基2H-呋喃并[2,3-c]吡喃-2-酮 2H-呋喃并[2,3-c]吡喃-2-酮 2-[(1E,3E)-己-1,3-二烯基]-2,6-二甲基-5,6-二氢呋喃并[5,4-b]吡喃-3,4-二酮 (3aS,5S,6R,9E,14R,15R,15aR)-2,3,3a,4,5,6,7,8,11,12,13,14,15,15alpha-十四氢-6,10,14-三甲基-3-亚甲基-2-氧代-5,15-环氧环十四烷并[b]呋喃-6-醇乙酸酯 (3aR,4S,7aR)-4-羟基-3,3a,4,7a-四氢呋喃并[5,4-b]吡喃-2-酮 (3aα,3bβ,6aβ,7aα)-(+/-)-hexahydro-6-hydroxy-3a-(phenylmethyl)difuro<2,3-b:3',4'-d>furan-2(3H)-one (2R,3aS,4S,6S,7aR)-3a-benzyloxy-6-ethynyl-2-methoxy-4-p-methoxybenzyloxyhexahydrofuro[2,3-b]pyran (1R,2S,6S,7S)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester N3,5'-Cyclo-2',3'-O-isopropyliden-8-oxyguanosin (3aR,4aR,7aS,8aS)-2-Thioxo-hexahydro-furo[3',4':4,5]benzo[1,2-d][1,3]dioxol-5-one 9-(3',5'-O-Isopropyliden-2-keto-β-D-xylofuranosyl)-adenin (1aR,1bS,4aS,5aS)-1a-Isopropyl-hexahydro-1,4-dioxa-cyclopropa[a]pentalen-3-one [(3aR,4S,6R,7S,7aR)-7-acetyloxy-2-oxo-4-phenylsulfanyl-3,3a,4,6,7,7a-hexahydropyrano[3,4-d][1,3]oxazol-6-yl]methyl acetate (2R,3R,3aS,6R,7R,7aR)-7-azido-6-methoxy-2-phenylsulfanyl-hexahydrofuro[3,2-b]pyran-3-ol 7-Dihydroxymethyl-O1,O2-isopropyliden-3,7-anhydro-6-desoxy-D-glucofuranose (1S,2S,6S,7R)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester (2R,3S)-2-Methyl-4-oxo-oxetane-3-carboxylic acid (1R,5S)-6-methylene-3-oxo-bicyclo[3.2.1]oct-1-ylmethyl ester 3-C-(3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranosyl)-1-propene (2R,4aR,5aS,8aS,9S,9aR)-5a-methoxy-7-oxo-2-phenyloctahydrofuro[2',3':5,6]pyrano[3,2-d][1,3]dioxin-9-yl acetate (4R,5E,7R,9S,10S,11E,14S)-9-((benzyloxy)methoxy)-4,10-bis((tert-butyldimethylsilyl)oxy)-7-(dimethoxymethyl)-14-(furan-3-yl)-6,12-dimethyloxacyclotetradeca-5,11-dien-2-one 3-Furan-3-yl-8-methyl-5-(4,5,6,7-tetrahydro-isobenzofuran-4-yl)-2,7-dioxa-bicyclo[3.2.1]octane methyl 2,3"-anhydro-4,6-O-benzylidene-3-C-[2,2-dihydroxyethyl]-α-D-glucopyranoside (3aR,5S,6S,7aR)-5-((R)-but-3-en-2-yl)-6-hydroxyhexahydro-2H-furo[3,2-b]pyran-2-one 7-(3-Furan-3-yl-8-methyl-2,7-dioxa-bicyclo[3.2.1]oct-5-yl)-1,3,4,5,6,7-hexahydro-isobenzofuran-1-ol